Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2/PHASE3
Total Enrollment
119 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-10-19
Study Completion Date
2021-10-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting. The study will enrol adult subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis (SAR) induced by grass pollen exposure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
NCT05540717
Seasonal Allergic Rhinitis
Rhinoconjunctivitis
COMPLETED
PHASE3
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
NCT01385371
Rhinitis Allergic
Conjunctivitis
COMPLETED
PHASE3
A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis
NCT04881461
Allergy
COMPLETED
PHASE3
Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)
NCT00562159
Rhinoconjunctivitis
Rhinitis
Conjunctivitis
+1 more
COMPLETED
PHASE3
Efficacy and Safety of Grass Pollen Sublingual Immunotherapy
NCT00567346
Allergic Rhinoconjunctivitis
COMPLETED
PHASE2/PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PQGrass309 is a randomised, double-blind, placebo-controlled exploratory study to explore the efficacy and safety of PQ Grass 27600 SU in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis (SAR) induced by grass pollen exposure. The study is expected to be conducted in the United States (US) and the European Union (EU). The study will enrol enough subjects to allow treatment of approximately 150 subjects.
The aim of this exploratory field study is to explore amongst others the following:
* The efficacy and safety (up to 6 months following treatment) of a cumulative dose of 27600 standardised units (SU) of PQ Grass in the treatment of grass pollen allergy.
* The expected average treatment effect on combined symptom and medication score.
The aim of this exploratory field study is to explore amongst others the following:
* The efficacy and safety (up to 6 months following treatment) of a cumulative dose of 27600 standardised units (SU) of PQ Grass in the treatment of grass pollen allergy.
* The expected average treatment effect on combined symptom and medication score.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Rhinitis, Allergic, Seasonal
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PQ Grass Standard Dosing Regimen
Cumulative dose 27600 SU
Group Type
EXPERIMENTAL
PQ Grass
Intervention Type
BIOLOGICAL
Suspension for injection
PQ Grass Alternative Dosing Regimen
Cumulative dose 27600 SU
Group Type
EXPERIMENTAL
PQ Grass
Intervention Type
BIOLOGICAL
Suspension for injection
Placebo Option 1
Suspension for injection
Group Type
PLACEBO_COMPARATOR
Placebo Option 1
Intervention Type
DRUG
Suspension for injection
Placebo option 2
Solution for injection
Group Type
PLACEBO_COMPARATOR
Placebo Option 2
Intervention Type
DRUG
Solution for injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PQ Grass
Suspension for injection
Intervention Type
BIOLOGICAL
Placebo Option 1
Suspension for injection
Intervention Type
DRUG
Placebo Option 2
Solution for injection
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\- Informed Consent
1. Capable of giving signed informed consent and demonstrates willingness to comply with the requirements and restrictions listed in the ICF and study protocol and to attend required study visits.
2. Subject who has signed and dated the ICF.
\- Age:
3. 18 to 65 years of age inclusive, at the time of signing the ICF.
\- Sex / Contraceptive requirements:
4. Male or female.
5. Female subjects who are not of childbearing potential (defined as at least 12 months natural spontaneous amenorrhoea, or at least 6 weeks following surgical menopause) or females of childbearing potential who agree to comply with the contraceptive requirements of the study protocol.
\- Subjects and general health characteristics:
6. Good general health, as determined by the investigator, based on a medical evaluation, including medical history, physical examination, and laboratory tests. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
7. Positive history of moderate to severe symptoms of seasonal allergic rhinitis and/or rhinoconjunctivitis ascribed to grass (Pooideae) pollen exposure that required repeated use of antihistamines, nasal corticosteroids, and/or leukotriene modifiers for relief of symptoms during the last 2 consecutive seasons prior to the study, confirmed by subject records.
Please note: Subjects with asthma may be included, but the asthma must be well controlled (according to current Global Initiative for Asthma {GINA} guidelines \[GINA, 2020\]).
8. A positive SPT for grass pollen (wheals \[longest diameter\] ≥3 mm and histamine ≥3 mm) and a negative SPT to the negative control (wheal diameter =0) at screening.
9. Grass specific IgE class ≥2 as documented by an ImmunoCAP test at screening.
10. FEV1 ≥80% of predicted, with a FEV1/FVC ratio ≥70% and (PEFR) ≥75% predicted at screening.
11. Subjects who have no suspicion or symptoms of SARS-CoV-2 infection (as assessed by the investigator) or who have had no contact with a confirmed case of COVID-19 in the past 2 weeks prior to screening and randomisation.
1. Capable of giving signed informed consent and demonstrates willingness to comply with the requirements and restrictions listed in the ICF and study protocol and to attend required study visits.
2. Subject who has signed and dated the ICF.
\- Age:
3. 18 to 65 years of age inclusive, at the time of signing the ICF.
\- Sex / Contraceptive requirements:
4. Male or female.
5. Female subjects who are not of childbearing potential (defined as at least 12 months natural spontaneous amenorrhoea, or at least 6 weeks following surgical menopause) or females of childbearing potential who agree to comply with the contraceptive requirements of the study protocol.
\- Subjects and general health characteristics:
6. Good general health, as determined by the investigator, based on a medical evaluation, including medical history, physical examination, and laboratory tests. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
7. Positive history of moderate to severe symptoms of seasonal allergic rhinitis and/or rhinoconjunctivitis ascribed to grass (Pooideae) pollen exposure that required repeated use of antihistamines, nasal corticosteroids, and/or leukotriene modifiers for relief of symptoms during the last 2 consecutive seasons prior to the study, confirmed by subject records.
Please note: Subjects with asthma may be included, but the asthma must be well controlled (according to current Global Initiative for Asthma {GINA} guidelines \[GINA, 2020\]).
8. A positive SPT for grass pollen (wheals \[longest diameter\] ≥3 mm and histamine ≥3 mm) and a negative SPT to the negative control (wheal diameter =0) at screening.
9. Grass specific IgE class ≥2 as documented by an ImmunoCAP test at screening.
10. FEV1 ≥80% of predicted, with a FEV1/FVC ratio ≥70% and (PEFR) ≥75% predicted at screening.
11. Subjects who have no suspicion or symptoms of SARS-CoV-2 infection (as assessed by the investigator) or who have had no contact with a confirmed case of COVID-19 in the past 2 weeks prior to screening and randomisation.
Exclusion Criteria
\- Medical conditions:
1. Pregnant or lactating subject.
2. Moderate to severe allergy symptoms during the screening and treatment periods, and/or GPS caused by perennial allergens or seasonal allergens (other than grass) as verified by medical history and positive SPT.
Exception: screening, treatment and collection of eDiary data can be conducted outside of the pollen season(s) of concern or perennial allergies are irrelevant due to avoidance measures (e.g., cats and dog allergy).
3. Subjects with a positive SPT at US and EU sites in regions with relevant southern grass (Bahia grass, Bermuda grass or Johnson grass) exposure.
4. Moderate to severe symptoms during the 3 years prior to Visit 1 to another seasonal or perennial allergen not tested in the SPT that cannot be avoided during the study and the symptoms of which may interfere with administration of treatment and /or impact the data collected, as determined by the investigator.
5. Presence of any medical condition that may reduce the ability to survive a serious allergic reaction.
6. History of autoimmune disease including Hashimoto's thyroiditis or other immunological disorder or other diseases (including, but not limited to, malignancy, cardiovascular, gastro-intestinal, hepatic, renal, hematological, neurological, endocrine or pulmonary disease) that in the opinion of the investigator may pose a safety risk or compromise the interpretation of efficacy of the study treatment.
7. Presence of severe or uncontrolled or partly controlled asthma as defined in the GINA guidelines (GINA 2020) or asthma that requires more than a daily dose above 400 mcg of inhaled budesonide or equivalent.
8. Emergency room visit or hospitalisation for asthma in the 12 months prior to screening and randomisation or any history of a life-threatening asthma attack.
9. Presence of non-atopic rhinitis and/or rhino-sinusitis (with or without polyps).
10. Presence of nasal polyps and/or chronic sinusitis.
11. Presence of any acute or chronic ocular disorder, other than allergic conjunctivitis, which could interfere with the evaluation of CPT.
12. Eye surgery within the past 6 months.
13. Presence of any skin conditions (e.g. skin abnormalities, tattoos) which might interfere with the interpretation of the SPT results.
14. Clinical history of Type I diabetes. Subjects with well-controlled Type II diabetes will be allowed to participate at the discretion of the investigator.
15. Any acute infection (including upper respiratory tract infections in the 14 days prior to Visit 2), which in the opinion of the investigator may pose a safety risk to the subject.
16. Clinical history of severe or serious systemic reaction in response to AIT treatment in the past.
17. Clinical history of severe or life-threatening anaphylactic reactions to foods, insect venom, exercise, drugs or idiopathic anaphylaxis.
18. Clinical history of allergy, hypersensitivity or intolerance to the excipients of the IMP.
19. Tyrosine metabolism disorders, especially tyrosinemia and alkaptonuria.
\- Prior/concomitant therapy:
20. History of any allergen SIT.
21. Inability to adhere to the washout periods for Prohibited Medications/Therapies with respect to Visit 1/1a and to refrain from using the medications indicated until after Visit 15.
22. Treatment with a preparation containing MPL (e.g., Cervarix, Shingrix, Fendrix) within 2 years prior to Visit 1 and until after completion of Visit 15 (with the exception of the IMP).
23. Unable to receive epinephrine therapy (i.e., use of epinephrine is contraindicated such as in subjects with hyperthyroidism, uncontrolled hypertension, cardiac arrhythmias, closed angle glaucoma or subjects taking other sympathomimetic).
24. Previous history of epinephrine device use.
25. β-blocker medication (including eye drops), for any indication.
26. Monoamine oxidase inhibitors and tricyclic antidepressants. (Tricyclic antidepressants should be avoided at least 2 weeks prior to screening).
27. Any previous therapy (within 12 months prior to screening) or current therapy with anti IgE (e.g., Xolair) or anti-interleukins (e.g., mepolizumab) or any other therapy with a biologic agent.
28. Unable to refrain from any vaccination (including influenza and any potential vaccine for COVID-19) during the study (unless administered more than 30 days prior to randomisation). Please note: Emergency vaccinations (e.g., tetanus due to injury) can be administered at any time.
29. Current or past therapy (within the previous 5 years) with immunosuppressant drugs or immunomodulatory biologics.
Other exclusions
30. Clinical history of drug or alcohol abuse which, in the investigator's opinion, could interfere with the subject's ability to participate in the study.
31. Participation in a clinical research trial with any IMP within 4 weeks of Visit 1 or concomitantly with this study
32. Personal, financial or other dependent relationship (e.g., employee or immediate relative) with the study site, Sponsor, Sponsor's representative, or another individual who has access to the study protocol.
33. Vulnerable subjects or those in judicial or governmental detention, detainment or imprisonment in a public institution.
34. Subjects likely to have prolonged periods of absence (e.g., business or personal travel) during the GPS defined as:
* Absence of 22 days or more in similar or mixed geographic regions as determined by the investigator, with no single trip in a similar geographical region exceeding 14 days and no single trip in a non-similar geographical region exceeding 7 days,
* Absence of 15 days or more in non-similar geographic regions as determined by the investigator, with no single trip exceeding 7 days.
35. Have changed residence between geographical regions since the last GPS. Exception: the old and new residences are in the same or similar geographical region as determined by the investigator.
1. Pregnant or lactating subject.
2. Moderate to severe allergy symptoms during the screening and treatment periods, and/or GPS caused by perennial allergens or seasonal allergens (other than grass) as verified by medical history and positive SPT.
Exception: screening, treatment and collection of eDiary data can be conducted outside of the pollen season(s) of concern or perennial allergies are irrelevant due to avoidance measures (e.g., cats and dog allergy).
3. Subjects with a positive SPT at US and EU sites in regions with relevant southern grass (Bahia grass, Bermuda grass or Johnson grass) exposure.
4. Moderate to severe symptoms during the 3 years prior to Visit 1 to another seasonal or perennial allergen not tested in the SPT that cannot be avoided during the study and the symptoms of which may interfere with administration of treatment and /or impact the data collected, as determined by the investigator.
5. Presence of any medical condition that may reduce the ability to survive a serious allergic reaction.
6. History of autoimmune disease including Hashimoto's thyroiditis or other immunological disorder or other diseases (including, but not limited to, malignancy, cardiovascular, gastro-intestinal, hepatic, renal, hematological, neurological, endocrine or pulmonary disease) that in the opinion of the investigator may pose a safety risk or compromise the interpretation of efficacy of the study treatment.
7. Presence of severe or uncontrolled or partly controlled asthma as defined in the GINA guidelines (GINA 2020) or asthma that requires more than a daily dose above 400 mcg of inhaled budesonide or equivalent.
8. Emergency room visit or hospitalisation for asthma in the 12 months prior to screening and randomisation or any history of a life-threatening asthma attack.
9. Presence of non-atopic rhinitis and/or rhino-sinusitis (with or without polyps).
10. Presence of nasal polyps and/or chronic sinusitis.
11. Presence of any acute or chronic ocular disorder, other than allergic conjunctivitis, which could interfere with the evaluation of CPT.
12. Eye surgery within the past 6 months.
13. Presence of any skin conditions (e.g. skin abnormalities, tattoos) which might interfere with the interpretation of the SPT results.
14. Clinical history of Type I diabetes. Subjects with well-controlled Type II diabetes will be allowed to participate at the discretion of the investigator.
15. Any acute infection (including upper respiratory tract infections in the 14 days prior to Visit 2), which in the opinion of the investigator may pose a safety risk to the subject.
16. Clinical history of severe or serious systemic reaction in response to AIT treatment in the past.
17. Clinical history of severe or life-threatening anaphylactic reactions to foods, insect venom, exercise, drugs or idiopathic anaphylaxis.
18. Clinical history of allergy, hypersensitivity or intolerance to the excipients of the IMP.
19. Tyrosine metabolism disorders, especially tyrosinemia and alkaptonuria.
\- Prior/concomitant therapy:
20. History of any allergen SIT.
21. Inability to adhere to the washout periods for Prohibited Medications/Therapies with respect to Visit 1/1a and to refrain from using the medications indicated until after Visit 15.
22. Treatment with a preparation containing MPL (e.g., Cervarix, Shingrix, Fendrix) within 2 years prior to Visit 1 and until after completion of Visit 15 (with the exception of the IMP).
23. Unable to receive epinephrine therapy (i.e., use of epinephrine is contraindicated such as in subjects with hyperthyroidism, uncontrolled hypertension, cardiac arrhythmias, closed angle glaucoma or subjects taking other sympathomimetic).
24. Previous history of epinephrine device use.
25. β-blocker medication (including eye drops), for any indication.
26. Monoamine oxidase inhibitors and tricyclic antidepressants. (Tricyclic antidepressants should be avoided at least 2 weeks prior to screening).
27. Any previous therapy (within 12 months prior to screening) or current therapy with anti IgE (e.g., Xolair) or anti-interleukins (e.g., mepolizumab) or any other therapy with a biologic agent.
28. Unable to refrain from any vaccination (including influenza and any potential vaccine for COVID-19) during the study (unless administered more than 30 days prior to randomisation). Please note: Emergency vaccinations (e.g., tetanus due to injury) can be administered at any time.
29. Current or past therapy (within the previous 5 years) with immunosuppressant drugs or immunomodulatory biologics.
Other exclusions
30. Clinical history of drug or alcohol abuse which, in the investigator's opinion, could interfere with the subject's ability to participate in the study.
31. Participation in a clinical research trial with any IMP within 4 weeks of Visit 1 or concomitantly with this study
32. Personal, financial or other dependent relationship (e.g., employee or immediate relative) with the study site, Sponsor, Sponsor's representative, or another individual who has access to the study protocol.
33. Vulnerable subjects or those in judicial or governmental detention, detainment or imprisonment in a public institution.
34. Subjects likely to have prolonged periods of absence (e.g., business or personal travel) during the GPS defined as:
* Absence of 22 days or more in similar or mixed geographic regions as determined by the investigator, with no single trip in a similar geographical region exceeding 14 days and no single trip in a non-similar geographical region exceeding 7 days,
* Absence of 15 days or more in non-similar geographic regions as determined by the investigator, with no single trip exceeding 7 days.
35. Have changed residence between geographical regions since the last GPS. Exception: the old and new residences are in the same or similar geographical region as determined by the investigator.
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergy Therapeutics
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pieter-Jan de Kam, Ph.D
Role: STUDY_DIRECTOR
Clinical Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Allergy and Asthma Associates of Bluegrass
Lexington, Kentucky, United States
Site Status
Chesapeake Clinical Research, Inc.
White Marsh, Maryland, United States
Site Status
Atlantic Research Center, LLC
Ocean Township, New Jersey, United States
Site Status
Smith Allergy & Asthma Specialists
Cortland, New York, United States
Site Status
Corning Center for Clinical Research
Horseheads, New York, United States
Site Status
Allergy Partners of Western North Carolina
Asheville, North Carolina, United States
Site Status
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio, United States
Site Status
Allergy Asthma & Sinus Center, S.C.
Greenfield, Wisconsin, United States
Site Status
Universitatsmedizin Berlin - Charite Campus Mitte - Allergie Centrum Charite
Berlin, , Germany
Site Status
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Dresden, , Germany
Site Status
ENT RESEARCH - Institut für klinische Studien
Essen, , Germany
Site Status
Medaimun GmbH
Frankfurt am Main, , Germany
Site Status
Hamburger Institut für Therapieforschung GmbH
Hamburg, , Germany
Site Status
Studienzentrum Dr. Sabine Laßmann
Saalfeld, , Germany
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Germany
References
Explore related publications, articles, or registry entries linked to this study.
Layhadi JA, Starchenka S, De Kam PJ, Palmer E, Wu LYD, Keane ST, Fulton WT, Hikmawati P, Meng X, Filipaviciute P, Cutrina Pons A, Oluwayi K, Lis K, Armfield O, Skinner MA, Heath MD, Hewings SJ, Kramer MF, Shamji MH. Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study. Allergy. 2025 Jul 8. doi: 10.1111/all.16640. Online ahead of print.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-000408-13
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
PQGrass309
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis
NCT00812799
UNKNOWN
PHASE3
Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat Rhinoconjunctivitis
NCT00550875
COMPLETED
PHASE2
Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis
NCT00263601
COMPLETED
PHASE3
The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)
NCT00276016
COMPLETED
PHASE3
Efficacy and Safety of Grass-SPIRE Registration Study
NCT02795273
WITHDRAWN
PHASE2/PHASE3
Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis
NCT00309036
COMPLETED
PHASE3
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
NCT02582073
COMPLETED
PHASE2
A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL
NCT02557633
COMPLETED
PHASE1
Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis
NCT02245360
COMPLETED
PHASE3
Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber
NCT06104293
COMPLETED
NA
Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
NCT02654223
COMPLETED
PHASE2
ToleroMune Grass Exposure Unit Study
NCT01385800
COMPLETED
PHASE2
Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge
NCT01657097
COMPLETED
PHASE4
Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis
NCT00813046
COMPLETED
PHASE1
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
NCT00550550
COMPLETED
PHASE3
Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED)
NCT00673062
COMPLETED
PHASE2
Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration
NCT00777374
COMPLETED
PHASE2
Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
NCT02560948
COMPLETED
PHASE3
Long-term Efficacy and Safety Study With Oralgen Grass Pollen
NCT00824447
COMPLETED
PHASE2/PHASE3
Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis
NCT00833066
COMPLETED
PHASE1/PHASE2
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
NCT04502966
COMPLETED
PHASE2
Ragweed Observational Study
NCT01398137
COMPLETED
A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment
NCT00773240
COMPLETED
PHASE3
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
NCT00619827
COMPLETED
PHASE1
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
NCT01308021
COMPLETED
PHASE2